425: Mallinckrodt Reports Strong Q1 2025 Results, Raises Acthar Guidance Amidst Endo Merger Plans

Mallinckrodt announces positive Q1 2025 results with top-line growth and increased Acthar sales, while progressing towards its merger with Endo expected in the second half of 2025.

Summary

• Mallinckrodt reported a strong start to 2025, building on positive momentum from 2024.
• First quarter net sales were $419.9 million, a 10.2% decrease compared to Q1 2024, but grew by 2.5% excluding the Therakos divestiture.
• Acthar sales grew by 12.3%, marking the fifth consecutive quarter of growth, driven by the successful launch of the SelfJect device, which now accounts for over 70% of new Acthar prescriptions.
• The company is raising its 2025 net sales guidance for Acthar to a high single-digit range.
• INOmax sales were impacted by competition in the U.S. market, but saw 12% growth in Japan.
• Terlivaz sales increased by 23.3%.
• Specialty Generics segment delivered its ninth consecutive quarter of net sales growth, up 1%.
• The company is progressing with its planned combination with Endo, expecting it to close in the second half of 2025.
• Net loss for the quarter was $27.7 million, an improvement from the $65.4 million loss in the prior year period.
• Adjusted EBITDA was $102.3 million, compared to $144.9 million in the prior year period.
• The company ended the quarter with a cash balance of $422.2 million and net debt of $451.4 million, with a net debt leverage ratio of 0.8 times.
• Full-year 2025 guidance is reiterated, with expected net sales between $1.7 billion and $1.8 billion and adjusted EBITDA between $480 million and $520 million.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook, highlighting growth in key products and progress towards the merger with Endo. While there are some challenges, the overall tone is optimistic and confident.

Positives

• Acthar Gel sales are growing, driven by the successful launch of the SelfJect device.
• Terlivaz sales are increasing.
• Specialty Generics segment continues to show consistent growth.
• The company is progressing with its planned combination with Endo.
• Net loss has decreased compared to the prior year period.
• The company has a strong cash position and has reduced its net debt significantly.
• The company is raising its 2025 net sales guidance for Acthar to a high single-digit range.

Negatives

• Overall net sales decreased by 10.2% compared to Q1 2024, although this is largely due to the Therakos divestiture.
• INOmax sales continue to be impacted by competition in the U.S. market.
• Adjusted EBITDA decreased compared to the prior year period, driven by the Therakos divestiture, incremental commercial investments for Acthar Gel, and the impact of nitric oxide competition in the U.S.
• Hospital demand growth for Terlivaz has not been as strong as desired.

Risks

• Competition in the U.S. market is impacting INOmax sales.
• Global competitive pressure is affecting the API business, particularly APAP products.
• The company faces risks related to the successful integration of Mallinckrodt and Endo's businesses.
• The company faces risks related to obtaining shareholder approval for the proposed business combination transaction.
• The company faces risks related to regulatory approval for the proposed business combination transaction.
• The company faces risks related to potential litigation relating to the proposed transactions.
• The company faces risks related to potential changes in Mallinckrodt's business strategy and performance.
• The company faces risks related to governmental investigations and inquiries, regulatory actions, and lawsuits, in each case related to Mallinckrodt or its officers.
• The company faces risks related to compliance with and restrictions under the global settlement to resolve all opioid-related claims.
• The company faces risks related to matters related to Acthar Gel, including the settlement with governmental parties to resolve certain disputes and compliance with and restrictions under the related corporate integrity agreement.
• The company faces risks related to the ability to maintain relationships with Mallinckrodt's suppliers, customers, employees and other third parties following the emergence from the 2023 bankruptcy proceedings.
• The company faces risks related to scrutiny from governments, legislative bodies and enforcement agencies related to sales, marketing and pricing practices.
• The company faces risks related to pricing pressure on certain of Mallinckrodt's products due to legal changes or changes in insurers or other payers reimbursement practices resulting from recent increased public scrutiny of healthcare and pharmaceutical costs.
• The company faces risks related to the reimbursement practices of governmental health administration authorities, private health coverage insurers and other third-party payers.
• The company faces risks related to complex reporting and payment obligations under the Medicare and Medicaid rebate programs and other governmental purchasing and rebate programs.
• The company faces risks related to cost containment efforts of customers, purchasing groups, third-party payers and governmental organizations.
• The company faces risks related to changes in or failure to comply with relevant laws and regulations.
• The company faces risks related to any undesirable side effects caused by Mallinckrodt's approved and investigational products, which could limit their commercial profile or result in other negative consequences.
• The company faces risks related to Mallinckrodt's and its partners ability to successfully develop, commercialize or launch new products or expand commercial opportunities of existing products, including Acthar Gel (repository corticotropin injection) SelfJect and the INOmax Evolve DS delivery system.
• The company faces risks related to Mallinckrodt's ability to successfully identify or discover additional products or product candidates.
• The company faces risks related to Mallinckrodt's ability to navigate price fluctuations and pressures, including the ability to achieve anticipated benefits of price increases of its products.
• The company faces risks related to competition.
• The company faces risks related to Mallinckrodt's ability to protect intellectual property rights, including in relation to ongoing and future litigation.
• The company faces risks related to limited clinical trial data for Acthar Gel.
• The company faces risks related to the timing, expense and uncertainty associated with clinical studies and related regulatory processes.
• The company faces risks related to product liability losses and other litigation liability.
• The company faces risks related to material health, safety and environmental laws and related liabilities.
• The company faces risks related to business development activities or other strategic transactions.
• The company faces risks related to attraction and retention of key personnel.
• The company faces risks related to the effectiveness of information technology infrastructure, including risks of external attacks or failures.
• The company faces risks related to customer concentration.
• The company faces risks related to Mallinckrodt's reliance on certain individual products that are material to its financial performance.
• The company faces risks related to Mallinckrodt's ability to receive sufficient procurement and production quotas granted by the U.S. Drug Enforcement Administration.
• The company faces risks related to complex manufacturing processes.
• The company faces risks related to reliance on third-party manufacturers and supply chain providers and related market disruptions.
• The company faces risks related to conducting business internationally.
• The company faces risks related to Mallinckrodt's significant levels of intangible assets and related impairment testing.
• The company faces risks related to natural disasters or other catastrophic events.
• The company faces risks related to Mallinckrodt's substantial indebtedness and settlement obligation, its ability to generate sufficient cash to reduce its indebtedness and its potential need and ability to incur further indebtedness.
• The company faces risks related to restrictions contained in the agreements governing Mallinckrodt's indebtedness and settlement obligation on Mallinckrodt's operations, future financings and use of proceeds.
• The company faces risks related to Mallinckrodt's variable rate indebtedness.
• The company faces risks related to Mallinckrodt's tax treatment by the Internal Revenue Service under Section 7874 and Section 382 of the Internal Revenue Code of 1986, as amended.
• The company faces risks related to future changes to applicable tax laws or the impact of disputes with governmental tax authorities.
• The company faces risks related to the impact of Irish laws.
• The company faces risks related to the impact on the holders of Mallinckrodt's ordinary shares if Mallinckrodt were to cease to be a reporting company in the United States.
• The company faces risks related to the comparability of Mallinckrodt's post-emergence financial results and the projections filed with the Bankruptcy Court.
• The company faces risks related to the lack of comparability of Mallinckrodt's historical financial statements and information contained in its financial statements after the adoption of fresh-start accounting following emergence from the 2023 bankruptcy proceedings.

Future Outlook

Mallinckrodt reiterates its full-year 2025 guidance, expecting net sales between $1.7 billion and $1.8 billion and adjusted EBITDA between $480 million and $520 million. The company anticipates closing the merger with Endo in the second half of 2025.

Management Comments

• Siggi Olafsson stated that Mallinckrodt had a great start to the year and continued to build on positive momentum from 2024.
• Siggi Olafsson highlighted the strong performance of Acthar, driven by the SelfJect device, and the ongoing rollout of the INOmax Evolve DS delivery system.
• Siggi Olafsson expressed excitement for the planned combination with Endo, stating it will create a global scale diversified pharmaceutical leader.
• Bryan Reasons noted that the company is in pretty good shape regarding tariffs and doesn't have a ton of exposure.
• Siggi Olafsson stated that the company is well-positioned regarding tariffs due to having most of its manufacturing in the U.S.

Industry Context

The announcement comes amid ongoing consolidation in the pharmaceutical industry, with companies seeking to achieve greater scale and diversification. Mallinckrodt's merger with Endo is part of this trend, aiming to create a more competitive player in the global market. The discussion of tariffs and manufacturing locations reflects the increasing focus on supply chain security and the potential impact of trade policies on pharmaceutical companies.

Comparison to Industry Standards

• Mallinckrodt's performance can be compared to other specialty pharmaceutical companies such as Teva, Viatris, and Bausch Health.
• The 2.5% net sales growth (excluding Therakos) is a key metric to compare against the growth rates of these peers.
• Acthar's growth is notable, as many companies are facing pricing pressures and competition in the specialty drug market.
• The company's net debt leverage ratio of 0.8 times is relatively low, indicating a healthy balance sheet compared to some of its more leveraged peers.
• The reiterated full-year guidance provides a benchmark for investors to assess the company's future performance against industry expectations.

Stakeholder Impact

• Shareholders can expect potential value creation through the merger with Endo and continued growth in key products.
• Patients will benefit from the continued availability of important treatments like Acthar, INOmax, and Terlivaz.
• Employees face potential changes and opportunities as the company integrates with Endo.
• Customers can expect continued supply of high-quality products and consistent service.
• Suppliers may see changes in procurement patterns as the company integrates with Endo.

Next Steps

• Complete the SEC process for the Form S4 registration statement.
• Hold shareholder meetings to consider and vote on the transaction with Endo.
• Continue the rollout of the INOmax Evolve DS delivery system.
• Continue efforts to expand adoption of Terlivaz.
• Work to close the merger with Endo in the second half of 2025.

Key Dates

Keywords

Mallinckrodt, Endo, Merger, Acthar, INOmax, Terlivaz, Specialty Generics, Pharmaceuticals, Financial Results, Q1 2025